Date Filed | Type | Description |
08/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
08/03/2023 |
8-K
| Quarterly results |
07/05/2023 |
8-K
| Quarterly results |
07/03/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
06/02/2023 |
4
| Gupta Suneel (Chief Development Officer) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 12,000 shares
@ $0 Paid exercise price by delivering 4,150 shares
@ $26.07, valued at
$108.2k
|
|
06/02/2023 |
4
| PATEL DINESH V PH D (President and CEO) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Gifted 10,000 shares
@ $0 Granted 30,000 shares
@ $0 Paid exercise price by delivering 12,165 shares
@ $26.07, valued at
$317.1k
|
|
06/02/2023 |
4
| Ali Asif (CFO) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 12,000 shares
@ $0 Paid exercise price by delivering 4,150 shares
@ $26.07, valued at
$108.2k
|
|
05/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/04/2023 |
8-K
| Quarterly results |
04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
04/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
03/20/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.6% stake in Protagonist Therapeutics, Inc. |
03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/15/2023 |
8-K
| Quarterly results |
03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/09/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 10% stake in Protagonist Therapeutics, Inc. |
01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.4% stake in Protagonist Therapeutics, Inc |
01/18/2023 |
4
| Giraudo Bryan (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
01/18/2023 |
4
| Williams Lewis T (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
01/18/2023 |
4
| Waddill William D. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
01/18/2023 |
4
| Noonberg Sarah B. (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
01/18/2023 |
4
| O'Dowd Sarah A (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
01/18/2023 |
4
| SELICK HAROLD E (Director) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 30,000 options to buy
@ $12.17, valued at
$365.1k
|
|
01/18/2023 |
4
| Gupta Suneel (Chief Development Officer) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 20,625 shares
@ $0 Granted 123,750 options to buy
@ $12.17, valued at
$1.5M
|
|
01/18/2023 |
4
| Ali Asif (CFO) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 10,625 shares
@ $0 Granted 63,750 options to buy
@ $12.17, valued at
$775.8k
|
|
01/18/2023 |
4
| MOLINA ARTURO MD (Chief Medical Officer) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Granted 3,125 shares
@ $0 Granted 18,750 options to buy
@ $12.17, valued at
$228.2k
|
|
01/18/2023 |
4
| PATEL DINESH V PH D (President and CEO) has filed a Form 4 on Protagonist Therapeutics, Inc
Txns:
| Gifted 3,000 shares
@ $0 Gifted 3,116 shares
@ $0 Granted 600,000 options to buy
@ $12.17, valued at
$7.3M
|
|
01/11/2023 |
SC 13G/A
| JOHNSON & JOHNSON reports a 5% stake in Protagonist Therapeutics, Inc. |
01/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 7.7% stake in AMENDED FILING PROTAGONIST THERAPEUTICS INC |
01/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|